老年患者干细胞移植：内科医生须知

What the internist should know about stem cell transplant in the elderly patient.

机构信息

Division of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; Division of Internal Medicine, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Division of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

出版信息

Eur J Intern Med. 2018 Dec;58:43-47. doi: 10.1016/j.ejim.2018.06.018. Epub 2018 Jun 28.

DOI:10.1016/j.ejim.2018.06.018

PMID:29960832

Abstract

Most hematological malignancies are increasing in frequency with age. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapeutic option for patients with malignant and non-malignant hematological diseases. The treatment of elderly patients with advanced hematological malignancies has expanded to include reduced intensity conditioning allo-HCT. Physicians increasingly refer older patients for allo-HCT due to more experience and improved supportive care in allo-HCT. This review article discusses the available data regarding the feasibility, tolerability, toxicity, and effectiveness of allo-HCT in different hematological diseases in the elderly. Over the past decade, utilization and survival after allo-HCT have increased in patients ≥70 years. Selected adults ≥70 years with hematological diseases should be evaluated for transplantation.

摘要

大多数血液系统恶性肿瘤的发病率随年龄增长而增加。异基因造血细胞移植（allo-HCT）是恶性和非恶性血液系统疾病患者潜在的治愈性治疗选择。对于晚期血液系统恶性肿瘤的老年患者，已扩展到包括强度降低的预处理 allo-HCT。由于 allo-HCT 方面有更多经验和改进的支持性护理，医生越来越多地将老年患者转诊进行 allo-HCT。本文综述了有关 allo-HCT 在老年人群中不同血液系统疾病中的可行性、耐受性、毒性和疗效的现有数据。在过去十年中，≥70 岁患者 allo-HCT 的应用和生存均有所增加。≥70 岁的患有血液系统疾病的特定成年人应评估其是否适合进行移植。